Isavuconazole for COVID-19-Associated Invasive Mold Infections

Isavuconazole is a broad-spectrum antifungal drug recently approved as a first-line treatment for invasive aspergillosis and as a first or alternative treatment for mucormycosis. The purpose of this review was to report and discuss the use of isavuconazole for the treatment of COVID-19-associated as...

Descripción completa

Detalles Bibliográficos
Autores principales: Ullah, Nadir, Sepulcri, Chiara, Mikulska, Malgorzata
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9323932/
https://www.ncbi.nlm.nih.gov/pubmed/35887431
http://dx.doi.org/10.3390/jof8070674

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9323932/
https://www.ncbi.nlm.nih.gov/pubmed/35887431
http://dx.doi.org/10.3390/jof8070674

Ejemplares similares